Wednesday, 25 April 2018 - 19:10
  • it
  • de
  • en
  • fr

Aducanumab

Gloomy results from the research for an Alzheimer’s therapy

Alzheimer’s is a pathology affecting 44 million people globally, with an extremely high social cost, which – for example – is close to $249bn pa in the US. Only four approved therapies are currently available to ease the effects of…

Alzheimer, significant results for Biogen’s aducanumab

Biogen today announced the results from an analysis of the long-term extension of its Phase Ib randomized, double-blind, placebo-controlled study of aducanumab, the investigational treatment for early Alzheimer’s disease. The new data include results from patients treated with aducanumab up…